Home/Pipeline/Eye‑D implant

Eye‑D implant

Glaucoma

Phase I/II completed, preparing for Phase IIIActive

Key Facts

Indication

Glaucoma

Phase

Phase I/II completed, preparing for Phase III

Status

Active

Company

Israel's sole publicly listed ophthalmology‑focused investment platform, BioLight builds a diversified portfolio of innovative eye‑care technologies.

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
INM-088	InMed Pharmaceuticals	Preclinical	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active
TODDD™ Platform	Amorphex Therapeutics	Pre-clinical	Active
Glaucoma Diagnostics	Avellino Laboratories	Development/Accreditation	Active